Microarray data analysis to identify crucial genes regulated by CEBPB in human SNB19 glioma cells.

BACKGROUND: Glioma is one of the most common primary malignancies in the brain or spine. The transcription factor (TF) CCAAT/enhancer binding protein beta (CEBPB) is important for maintaining the tumor initiating capacity and invasion ability. To investigate the regulation mechanism of CEBPB in glioma, microarray data GSE47352 was analyzed.
METHODS: GSE47352 was downloaded from Gene Expression Omnibus, including three samples of SNB19 human glioma cells transduced with non-target control small hairpin RNA (shRNA) lentiviral vectors for 72 h (normal glioma cells) and three samples of SNB19 human glioma cells transduced with CEBPB shRNA lentiviral vectors for 72 h (CEBPB-silenced glioma cells). The differentially expressed genes (DEGs) were screened using limma package and then annotated. Afterwards, the Database for Annotation, Visualization, and Integrated Discovery (DAVID) software was applied to perform enrichment analysis for the DEGs. Furthermore, the protein-protein interaction (PPI) network and transcriptional regulatory network were constructed using Cytoscape software.
RESULTS: Total 529 DEGs were identified in the normal glioma cells compared with the CEBPB-silenced glioma cells, including 336 up-regulated and 193 down-regulated genes. The significantly enriched pathways included chemokine signaling pathway (which involved CCL2), focal adhesion (which involved THBS1 and THBS2), TGF-beta signaling pathway (which involved THBS1, THBS2, SMAD5, and SMAD6) and chronic myeloid leukemia (which involved TGFBR2 and CCND1). In the PPI network, CCND1 (degree = 29) and CCL2 (degree = 12) were hub nodes. Additionally, CEBPB and TCF12 might function in glioma through targeting others (CEBPB → TCF12, CEBPB → TGFBR2, and TCF12 → TGFBR2).
CONCLUSIONS: CEBPB might act in glioma by regulating CCL2, CCND1, THBS1, THBS2, SMAD5, SMAD6, TGFBR2, and TCF12.

Background

Glioma, which is known as one of the most common primary malignancies in the brain or spine, accounts for nearly 30 % of all brain and central nervous system tumors and 80 % of all malignant brain tumors [1, 2]. Previous researches have shown that the most important hallmarks of malignant glioma are its invasion and angiogenesis [3]. So far, researchers have indicated that glioma can be induced by neurofibromatoses and tuberous sclerosis complex [4], electromagnetic radiation [5], DNA repair genes (such as excision repair cross-complementing 1, ERCC1, and X-ray repair cross-complementing group 1, XRCC1) [6]. However, the exact molecular mechanisms of glioma were still unclear.

In the central nervous system, the neoplastic transformation can convert the neural cells into cells of mesenchymal phenotype which possess the ability of invasion and promoting angiogenesis [7, 8]. What is more, it has been identified that mesenchymal stem cells (MSC)-like properties may play a role in the tumorigenesis, invasion, and recurrence of primary glioblastoma tumors [8]. The transcription factor (TF) CCAAT/enhancer binding protein beta (CEBPB) is associated with the mesenchymal state of primary glioblastoma, and its expression in glioma is important for maintaining the tumor initiating capacity and invasion ability [9, 10]. Moreover, the transforming growth factor beta 1/SMAD family member 3 (TGFB1/SMAD3) plays a key role in the extracellular matrix (ECM) production which can lead to glioblastoma aggression [11, 12]. It has been revealed that CEBPB can regulate the synthesis of ECM [13]. However, the regulation mechanism of CEBPB on TGFB1/SMAD3 in glioma was seldom studied.

In our study, in order to gain a better understanding of the regulation mechanisms of CEBPB and investigate whether CEBPB could regulate the production of ECM via the TGFB1/SMAD3 signaling pathway in glioma, the microarray data deposited by Carro et al. were further analyzed with bioinformatics methods. Firstly, the differentially expressed genes (DEGs) between SNB19 human glioma cells transduced with non-target control small hairpin RNA (shRNA) lentiviral vectors for 72 h and SNB19 human glioma cells transduced with CEBPB shRNA lentiviral vectors for 72 h were identified and annotated. Subsequently, their potential functions were predicted by enrichment analysis. Finally, protein-protein interaction (PPI) network and transcriptional regulatory network were constructed to screen key genes.

Methods

Microarray dataset

The microarray dataset of GSE19114 [14] was downloaded from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database, which was based on the platform of GPL6947 IlluminaHumanHT-12 V3.0 expression beadchip. A total of 74 samples were included in the dataset, among which 3 samples of SNB19 human glioma cells transduced with non-target control shRNA lentiviral vectors for 72 h (normal glioma cells) and 3 samples of SNB19 human glioma cells transduced with CEBPB shRNA lentiviral vectors for 72 h (CEBPB-silenced glioma cells) were used to study the effect of CEBPB on glioma.

Data preprocessing and DEGs screening

The preprocessed microarray data were obtained from GEO2R of National Center of Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/geo/geo2r/), including 48803 probes. The linear models for microarray data (limma) package [15] were used to identify the DEGs between the normal glioma cells and the CEBPB-silenced glioma cells. Benjamini-Hochberg (BH) method [16] was applied to adjust the raw p value into false discovery rate (FDR). The FDR <0.05 and |log2 fold change (FC) >1 were used as cut-off criteria.

Functional and pathway enrichment analysis

Gene Ontology (GO, http://www.geneontology.org/) annotations are of great importance for mining biological and functional significance from large dataset [17]. The Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.ad.jp/kegg) database represents higher order of functions in terms of the network of the interacting molecules [18]. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) online tool [19] was employed to perform GO functional and KEGG pathway enrichment analyses for the DEGs. The p value <0.05 was used as the cut-off criterion.

DEGs annotation

TSGene database (http://bioinfo.mc.vanderbilt.edu/TSGene/), which contains detailed annotations for each tumor suppressor gene (TSG), such as cancer mutations, gene expressions, methylation sites, transcriptional regulations, and PPIs, was applied to identify the TSGs from the DEGs [20]. Additionally, tumor-associated gene (TAG) database (http://www.binfo.ncku.edu.tw/TAG/), which provides information about commonly shared functional domains in well-characterized oncogenes and TSGs, was used for screening the TAGs from the DEGs [21]. Besides, as a collection of data about the transcriptional regulatory network, the Encyclopedia of DNA Elements (ENCODE) project was introduced for screening the TFs from the DEGs [22].

PPI network construction

The PPI pairs were searched using the Search Tool for the Retrieval of Interacting Genes (STRING, http://string-db.org/) online tool [23]. The required confidence (combined score) >0.4 was used as the cut-off criterion. Then, the Cytoscape software [24] was used to visualize the PPI network. Furthermore, connectivity degree analysis was performed to search the hub nodes of PPI networks. The degree of a node was corresponded to the number of interactions involved it [25]. In addition, hub nodes were nodes with higher degrees.

Transcriptional regulatory network construction

ENCODE project is a collection of data about the transcriptional regulatory network, which helps illuminate TF-binding sites, histone marks, chromatin accessibility, DNA methylation, RNA expression, RNA binding, and other cell-state indicators [22]. Based on the transcriptional regulation interactions derived from ENCODE project, the regulatory network containing CEBPB and TGFB1/SMAD3 was constructed by Cytoscape software [24].

Results

Identification of DEGs

According to the analysis of the microarray dataset, a total of 529 DEGs (including 336 up-regulated genes and 193 down-regulated genes) were identified in the normal glioma cells compared with the CEBPB-silenced glioma cells. Among them, the top ten significantly up-regulated genes (such as thrombospondin 1 (THBS1) and chemokine (C-C motif) ligand 2 (CCL2)) and down-regulated genes (such as cyclin D1 (CCND1)) are displayed in Table 1.

Table 1

The top ten up- and down-regulated genes

DEGs	Gene symbol	FDR	Log2 FC
Up-regulated	AXL	9.39E−07	1.846031
	SERPINE1	8.58E−07	1.741651
	ITGB1	6.28E−08	1.739866
	PRPF31	6.28E−08	1.644503
	TXNDC5	3.26E−08	1.629988
	WDFY1	3.26E−08	1.622947
	AXL	1.57E−07	1.554728
	SLC1A3	5.96E−08	1.484443
	SET	3.90E−07	1.477058
	ITGB1	2.66E−07	1.466634
Down−regulated	AKR1B10	3.26E−08	−2.19537
	SLC2A3	6.28E−08	−2.01825
	HMOX1	6.28E−08	−1.58464
	CCND1	9.30E−08	−1.49158
	HIST1H2BK	1.16E−07	−1.38961
	STX3	3.36E−07	−1.2468
	TDG	8.98E−08	−1.23629
	SRXN1	8.97E−07	−1.22479
	DICER1	5.00E−07	−1.20817
	STK40	9.14E−07	−1.19625

DEGs differentially expressed genes, FDR false discovery rate, FC fold change

For the up-regulated genes, the enriched functions included transcription from RNA polymerase II promoter (p = 1.01E−03), cytoskeleton organization (p = 2.76E−04), and endocytosis (p = 2.57E−05) (Table 2A). Meanwhile, the down-regulated genes were mainly enriched in the function of enzyme-linked receptor protein signaling pathway (p = 2.89E−03), skin development (p = 4.97E−03), and response to hyperoxia (p = 2.97E−05) (Table 2B).

Table 2

The top ten functions enriched for the differentially expressed genes

GO ID	Description	Gene number	p value	Gene symbols
(A)
GO:0006366	Transcription from RNA polymerase II promoter	47	1.01E−03	SOX21, TCF25, TOP2A, GTF2F2, CIAO1, SERPINE1, DKK1, CYR61, SOX18, PAF1…
GO:0007010	Cytoskeleton organization	32	2.76E−04	PTK2, DPYSL2, CNN3, BICD2, CLIC4, CTGF, EDN1, NRAS, ITGB1, RHOG…
GO:0006897	Endocytosis	23	2.57E−05	PTK2, PIK3R2, THBS1, SERPINE1, DKK1, CYFIP2, AXL, RABEPK, LRP1B, ABCA1…
GO:0071375	Cellular response to peptide hormone stimulus	15	5.75E−04	PTK2, PIK3R2, GNG10, PPM1A, GNG5, PIK3R1, ATP6V1G1, NRAS, SOCS2, GNG12…
GO:0000398	mRNA splicing, via spliceosome	10	1.02E−02	PABPC1, GTF2F2, LSM7, LSM3, POLR2C, UPF3B, MBNL2, C1QBP, PRPF31, PAPOLA
GO:0048469	Cell maturation	9	8.96E−04	SOX18, AXL, GJA1, DLD, FOXO3,TYMS,CLN5,EPAS1,PTBP3
GO:0043200	Response to amino acid stimulus	7	6.71E−04	CTGF, EDN1, CEBPB, TYMS, CCL2, LAMTOR3, LAMTOR1
GO:0006112	Energy reserve metabolic process	7	4.38E−02	GNG10, GNG5, GFPT2, RAP1B, PPP1CC, GNG12, PYGB
GO:0018279	Protein N-linked glycosylation via asparagine	6	1.02E−02	UGGT1, MLEC, GFPT2, B4GALT5, PGM3, STT3B
GO:0006261	DNA-dependent DNA replication	6	1.49E−02	POLB, MCM3, RFC5, TOP2A, BAZ1A, RPAIN
(B)
GO:0007167	Enzyme-linked receptor protein signaling pathway	19	2.89E−03	KANK1, RTN4, ATP6V1D, PTPRK, EEF2K, ERRFI1, CGN, TGFBR2, ATP6V0A1, MVP…
GO:0043588	Skin development	9	4.97E−03	PTHLH, ALDH3A2, ERRFI1, YAP1, STK4, EMP1, COL5A2, NCOA3, DICER1
GO:0030330	DNA damage response, signal transduction by p53 class mediator	7	1.41E−04	NDRG1, SPRED1, PSME3, CDKN1A, E2F7, CASP2, HIPK2
GO:0001890	Placenta development	7	4.74E−04	TXNRD1, ADM, CCNF, SPP1, STK4, NDP, E2F7
GO:0031100	Organ regeneration	5	6.05E−05	ADM, TGFBR2, CCND1, LCP1, CDKN1A
GO:0071456	Cellular response to hypoxia	5	2.26E−03	HMOX1, NPEPPS, NDRG1, BNIP3, HIPK2
GO:0048002	Antigen processing and presentation of peptide antigen	5	4.35E−02	CTSD, NPEPPS, PSME3, AP1S1, AP1S2
GO:0055093	Response to hyperoxia	4	2.97E−05	TXNRD1, BNIP3, CAV1, CDKN1A
GO:0000188	Inactivation of MAPK activity	4	1.36E−04	DUSP5, SPRED1, CAV1, DUSP22
GO:0060443	Mammary gland morphogenesis	4	2.15E−03	PTHLH, TGFBR2, CAV1, NCOA3

GO Gene Ontology, ID identification

(A) The top ten functions enriched for the up-regulated genes. (B) The top ten functions enriched for the down-regulated genes

Among the up-regulated genes, CCL2 was significantly enriched in the pathway of chemokine signaling pathway (p = 1.63E−03). THBS1 and thrombospondin 2 (THBS2) were significantly involved in the pathway of focal adhesion (p = 7.54E−03). And the up-regulated genes, such as THBS1, THBS2, SMAD family member 5 (SMAD5) and SMAD family member 6 (SMAD6), were significantly enriched in transforming growth factor beta (TGF-beta) signaling pathway (p = 4.83E−02) (Table 3A). Meanwhile, the down-regulated transforming growth factor beta receptor II (TGFBR2) and CCND1 were significantly enriched in both the pathways of chronic myeloid leukemia (p = 9.85E−03) and pancreatic cancer (p = 4.69E−02) (Table 3B).

Table 3

The pathways enriched for the differentially expressed genes

KEGG ID	Name	Gene number	p value	Gene symbols
(A)
4062	Chemokine signaling pathway	12	1.63E−03	PTK2, PIK3R2, GNG10, GNG5, RAP1B, PIK3R1, NRAS, IL8, GNG12, CSK, FOXO3, CCL2
4510	Focal adhesion	11	7.54E−03	PTK2, PIK3R2, THBS1, THBS2, RAP1B, PPP1CC, PIK3R1, ITGB1, ACTG1, FLNB, CAV2
4810	Regulation of actin cytoskeleton	11	1.18E−02	PTK2, PIK3R2, CYFIP2, PPP1CC, PIK3R1, NRAS, ITGB1, GNG12, ACTG1, CSK, ARHGEF6
4910	Insulin signaling pathway	9	5.22E−03	PIK3R2, PPP1CC, PIK3R1, NRAS, SOCS2, PTPN1, PYGB, CALM2, PTPRF
3013	RNA transport	9	9.27E−03	PABPC1, EIF3A, NUP54, EIF3G, UPF3B, NUP155, KPNB1, NUP37, EIF2S3
4145	Phagosome	8	2.82E−02	TAP1, THBS1, THBS2, ATP6V1G1, ITGB1, ACTG1, LAMP2, DYNC1LI2
5100	Bacterial invasion of epithelial cells	7	1.24E−03	PTK2, PIK3R2, PIK3R1, ITGB1, RHOG, ACTG1, CAV2
5142	Chagas disease (American trypanosomiasis)	7	1.13E−02	PIK3R2, SERPINE1, GNA11, PIK3R1, IL8, IFNGR1, CCL2
4722	Neurotrophin signaling pathway	7	3.05E−02	PIK3R2, RAP1B, PIK3R1, NRAS, CALM2, CSK, FOXO3
4360	Axon guidance	7	3.28E−02	PTK2, DPYSL2, SEMA4F, NRAS, ITGB1, SLIT2, EFNA1
5131	Shigellosis	6	3.01E−03	ITGB1, IL8, RHOG, ACTG1, FBXW11, CSK
5211	Renal cell carcinoma	5	2.45E−02	PIK3R2, RAP1B, PIK3R1, NRAS, EPAS1
5412	Arrhythmogenic right ventricular cardiomyopathy (ARVC)	5	3.03E−02	ITGB1, DAG1, GJA1, ACTG1, CDH2
5410	Hypertrophic cardiomyopathy	5	4.62E−02	TPM3, ITGB1, DAG1, TPM1, ACTG1
4350	TGF-beta signaling pathway	5	4.83E−02	THBS1, THBS2, SMAD6, ID3, SMAD5
20	Citrate cycle (TCA cycle)	4	5.11E−03	CS, DLD, DLAT, SDHA
5144	Malaria	4	3.19E−02	THBS1, THBS2, IL8, CCL2
5213	Endometrial cancer	4	3.39E−02	PIK3R2, PIK3R1, NRAS, FOXO3
5223	Non-small cell lung cancer	4	3.82E−02	PIK3R2, PIK3R1, NRAS, FOXO3
3410	Base excision repair	3	4.23E−02	POLB, PARP1, PARP3
(B)
4144	Endocytosis	9	4.62E−04	ASAP2, VPS36, TGFBR2, ASAP1, CAV1, SH3KBP1, EHD1, RAB22A, DNM3
4142	Lysosome	7	4.55E−04	CTSD, TPP1, ATP6V0A1, ABCB9, AP1S1, AP1S2, NEU1
2010	ABC transporters	4	1.58E−03	ABCC2, ABCC3, ABCB9, ABCC5
10	Glycolysis/gluconeogenesis	4	6.56E−03	ENO2, ALDH3A2, PGAM1, PGK1
5220	Chronic myeloid leukemia	4	9.85E−03	TGFBR2, CCND1, CDKN1A, BCL2L1
561	Glycerolipid metabolism	3	1.98E−02	ALDH3A2, AGPAT9, LCLAT1
5212	Pancreatic cancer	3	4.69E−02	TGFBR2, CCND1, BCL2L1
4966	Collecting duct acid secretion	2	3.85E−02	ATP6V1D, ATP6V0A1
650	Butanoate metabolism	2	4.67E−02	AKR1B10, HMGCS1

(A) The pathways enriched for the up-regulated genes. (B) The pathways enriched for the down-regulated genes. Kyoto Encyclopedia of Genes and Genomes, KEGG; identification, ID

The annotation of DEGs

A total of 54 DEGs were screened as TAGs, including 33 up-regulated and 21 down-regulated genes. Among the 33 up-regulated genes, there were 22 TSGs (such as THBS1), 6 oncogenes, and 5 other genes (such as CCL2). Meanwhile, there were 13 TSGs, 4 oncogenes (such as CCND1), and 4 other genes in the 21 down-regulated genes. Additionally, 9 DEGs were screened as the TFs, including 8 up-regulated and 1 down-regulated genes (Table 4).

Table 4

The identified transcription factors (TFs) and tumor associated genes (TAGs) among the differentially expressed genes (DEGs). Tumor suppressed genes, TSGs

DEGs	TF numbers	TFs	TAG numbers	TAGs
				TSGs	Oncogenes	Others
Up-regulated	1	KLF12	33	BAP1, THBS1, DKK1, PAF1, ST13, LRP1B, PDGFRL, ITGB1, TPM1, GJA1, CDH11, SLIT2, GLIPR1, FAT1, SOD2, FOXO3, EFNA1, GAS1, PTPRF, RAD51C, CAV2, SDHA	SET, CCNA2, AXL, NRAS, ROS1, SCK	GTF2F2, CTGF, FHL2, C1QBP, CCL2
Down-regulated	8	ASCL1, ETV4, HSF1, LMO3, PML, RUNX3, TCF7, USF2	21	HIPK2, YAP1, ERRFI1, PTPRK, KANK1, BNIP3L, DUSP22, SASH1, CDKN1A, NDRG4, ZFHX3, NDRG1, TGFBR2,	BCL2L2, NCOA3, CCND1, CDC25B	PTHLH, EMP1, CAV1, GLS

PPI network analysis

The constructed PPI network was consisted of 810 interactions (such as CCND1-THBS1 and THBS1-CCL2) (Fig. 1). Besides, the top 10 % nodes with higher degrees in the PPI network were identified, including CCND1 (degree = 29) and CCL2 (degree = 12) (Table 5).

Fig. 1

The protein-protein interaction (PPI) network for the differentially expressed genes (DEGs). The red circles represent the up-regulated genes. The green circles indicate the down-regulated genes

Table 5

The top 10 % DEGs with higher degrees in the protein-protein interaction (PPI) network

Gene	Degree	Gene	Degree	Gene	Degree	Gene	Degree
CCND1	29	SOD2	19	CENPN	16	KIF11	15
PIK3R1	25	TYMS	19	CAV1	16	PTK2	15
PGK1	22	CDKN1A	18	PIK3R2	16	EDN1	14
NUP37	22	PARP1	18	CTGF	15	CS	13
CALM2	21	TOP2A	18	RFC5	15	CCL2	13
MCM3	21	ITGB1	18	NUP155	15	RSL24D1	12
GMNN	20	TCP1	18	NRAS	15	CDCA7	12
CCNA2	20	SERPINE1	17	NIP7	15	BCL2L1	12

Transcriptional regulatory network analysis

For further study, the regulation of TGFB1/SMAD3 by CEBPB, the transcriptional regulation interactions related to TGFB1/SMAD3, and the members of TGFB family were screened out from the ENCODE database and the transcriptional regulatory network was visualized by Cytoscape software (Fig. 2). The transcriptional regulation network showed that the CEBPB could regulate SMAD3, transcription factor 12 (TCF12), transforming growth factor beta 2 (TGFB2), TGFBR2, and TGFBR3 directly. Additionally, TCF12 targeted TGFB1, TGFBR1, TGFBR2, TGFBR3, and SMAD3.

Fig. 2

The transcriptional regulatory network involving CEBPB and TGFB1/SMAD3. The red and green nodes represent the up-regulated and down-regulated genes, respectively. The blue nodes stand for non-differentially expressed genes (DEGs). The arrows represent regulatory relationships

Discussion

In this study, a total of 529 DEGs were obtained, including 336 up-regulated genes and 193 down-regulated genes. Enrichment analysis indicated that the up-regulated CCL2 was significantly enriched in the chemokine signaling pathway. Reports have found that chemokine expressed by stromal cells or endogenously produced in glioma cells may play key roles in tumor cell migration, invasion, proliferation, angiogenesis and immune cell infiltration in the tumor mass [26]. The chemokine CCL2 can promote glioma tumor aggressiveness by promoting attraction of T regulatory cells (which suppress the lymphocyte anti-tumor effector function) and microglial cells (which can reduce the anti-tumor functions and secrete pro-invasive metalloproteinases) [27, 28]. Meanwhile, metalloproteinases can promote the glioma invasion through the detachment of ECM [29]. Besides, results of DEGs annotation showed that CCL2 was screened out as a TAG. Therefore, we speculated that the increased expression of CCL2 could promote glioma aggressiveness through the pathway of chemokine signaling.

In addition, some up-regulated genes (such as THBS1, THBS2, SMAD5, and SMAD6) were significantly enriched in the TGF-beta signaling pathway in our study. Recently, it has been reported that the TGFB is a key factor in controlling migration, invasion and angiogenesis in glioblastoma and induces profound immunosuppression [30]. Besides, the THBS1 (belonging to thrombospondin family), which is referred as a TGFB activating protein, induces the glioma invasion [31]. THBS1 is a powerful anti-angiogenesis protein in glioblastoma [32]. These suggested that THBS1 might play a key role in regulating the angiogenesis in glioma. As another member of thrombospondin family, THBS2 may be a potential inhibitor of tumor growth and angiogenesis [33]. Moreover, it has been shown that THBS2 can function as an endogenous inhibitor of angiogenesis through directly affecting endothelial cell migration, proliferation, survival, and apoptosis [34]. In our study, we also found that THBS1 and THBS2 were significantly involved in the pathway of focal adhesion. Previous study reported that focal adhesion can suppress the migration and metastasis of tumor cells [35]. Therefore, we speculated that THBS1 and THBS2 could regulate angiogenesis and invasion in glioma via TGF-beta signaling pathway and focal adhesion pathway. Former researches have shown that SMAD6 is an inhibitor of TGFB signaling and blocked the phosphorylation of receptor-regulated SMADs (such as SMAD5) in the cytoplasm [36]. As a result, we assumed that SMAD5 and SMAD6 might affect glioma by regulating the TGFB signaling. In the PPI network, THBS1 could interact with CCL2, to some extent, indicating that THBS1 might play key roles in glioma through regulating CCL2. Consequently, THBS1, THBS2, SAMD5 and SMAD6 could be key factors involved in the CEBPB-silenced glioma.

Moreover, CCND1, as a member of the cyclin family, possessed the highest degree in the PPI network. Cyclins can modulate tumor cell cycle through alterations in cyclin-dependent kinase activity [37]. What’s more, researchers have discovered that overexpression of CCND1 can elevate the proliferation and invasion potential of human glioblastoma cells [38]. In the PPI network, we also found that CCND1 had interaction with THBS1, suggesting that CCND1 could be involved in regulating proliferation and invasion of glioma via interacting with THBS1.

TGFBR2 plays a key role in TGFB signal propagation via activating TGFBR1 and the phosphorylation of SMAD proteins [39]. Moreover, silencing of TGFBR2 can abolish TGFB-induced invasion and migratory responses of glioblastoma in vitro [40]. In our study, we also discovered that the up-regulated TCF12 could regulate TGFB1 and SMAD3, indicating that CEBPB might regulate TGFB1 and SMAD3 through TCF12. Previous studies have shown that TGFB1/SMAD3 can promote tumor cell migration, invasion and metastasis through inducing epithelial-mesenchymal transition [41, 42]. What is more, TCF12 has been found to suppress the expression of E-cadherin, which can lead to the metastasis of tumor cells [43]. Therefore, we assumed that CEBPB might regulate TGFBR2 and SMAD3 through TGF-β1/SMAD3 signaling pathway in glioma, and CEBPB could also affect metastasis of glioma by regulating TCF12. However, in our study, TGFB1 and SMAD3 were not significantly expressed, which might due to the relatively short time for CEBPB silencing. In our further research, the regulation of CEBPB on TGFB1/SMAD3 will be studied with CEBPB-silenced for a relatively long time.

Conclusions

We conducted a comprehensive bioinformatics analysis to identify genes which may be correlated with CEBPB-silenced glioma. A total of 529 DEGs were identified in the normal glioma cells compared with the CEBPB-silenced glioma cells. Besides, The identified DEGs, such as TCF12, TGFBR2, CCL2, THBS1, THBS2, SMAD5, SMAD6, and CCND1, might play important roles in the progression of glioma via the regulation of CEBPB. However, further researches are still needed to unravel their action mechanisms in glioma.